Search

everythinglearnresearchcommunity

for

Search:↓

Researchers developed a method to label and study human hair follicle stem cells using a fluorescent protein.

Promising cancer treatments were found, but the manufacturer closed.

Researchers found a specific immune receptor in patients that causes severe skin reactions to a drug.

Antibody drug conjugates show promise in targeting cancer cells while reducing harm to healthy cells.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

AD198 is more effective than doxorubicin in stopping certain dog cancer cells.

Researchers found a specific T cell receptor linked to severe drug reactions like Stevens-Johnson syndrome when patients take carbamazepine.

RC48 shows promise for treating certain advanced cancers, but more research is needed.

A humanized CXCL12 antibody may delay and treat alopecia areata by altering the immune response.

CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.

PF-998425 is a new, effective, and non-phototoxic treatment for skin conditions related to androgens.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

The antibody 005-C04 blocks prolactin receptors, causing reversible infertility, impaired lactation, and hair regrowth in female mice.

Recombinant thrombomodulin can effectively treat severe complications in Cronkhite-Canada syndrome.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

A woman with severe angioedema improved significantly after treatment with rituximab.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

CAR-T cell therapy shows promise for treating autoimmune disorders but faces challenges like complex manufacturing and limited tissue penetration.

Blocking CCR5 can prevent and improve hair loss in alopecia areata.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

CT-707 is effective and safe for treating certain Chinese lung cancer patients.

CDK inhibitors may help treat ARDS and psoriasis but need more testing for safety and effectiveness.

PF-05314882 selectively activates androgen receptors without much effect on prostate and may help in prostate cancer treatment and hair loss prevention.